In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medivation, Inc.

http://www.medivation.com/

Latest From Medivation, Inc.

GSK Shoulder-To-Shoulder With CureVac Over COVID-19 Vaccine U-Turn

The UK major is delighted with the German biotech's decision to throw in the regulatory towel with CVnCoV and concentrate on the firms' collaboration to development a second-generation COVID-19 vaccine. However, GSK is insisting that the partners look at both modified as well as unmodified mRNA approaches, a significant change of strategy for CureVac.

Vaccines Coronavirus COVID-19

Deciphering Molnupiravir’s India Trial Discontinuation In Moderate COVID-19

Two Indian firms want to terminate specific Phase III trials for molnupiravir, the Merck/ Ridgeback Biotherapeutics’ antiviral in the spotlight as a treatment for mild-to-moderate COVID-19. Should much be read into these plans or is it merely an “administrative closure” that is being sought?

Research & Development Coronavirus COVID-19

CureVac Pulls Covid Vaccine From European Review Process

The company behind the CVnCOV COVID-19 vaccine candidate says the decision to withdraw from regulatory review is strategic. The EMA says outstanding issues affecting the benefit-risk balance remained to be answered at the time of withdrawal.

Europe Coronavirus COVID-19

Boehringer Buys Abexxa To Boost Cancer Pipeline

The latest in a series of deals that Boehringer Ingelheim has inked in the oncology space will see the German family-run firm acquire US biotech Abexxa.

M & A ImmunoOncology
See All

Company Information

UsernamePublicRestriction

Register